Overview

Data as of August 18, 2018 12:44 am EDT

Press Releases

Summary Toggle Madrigal Pharmaceuticals Reports 2018 Second Quarter Financial Results and Reviews Key Clinical Achievements

August 07, 2018

Madrigal’s MGL-3196 NASH abstract selected for oral presentation in the presidential plenary clinical session of The Liver Meeting® 2018 during the American Association for the Study of Liver Diseases 2018 Annual Meeting CONSHOHOCKEN, Pa. , Aug. 07, 2018 (GLOBE NEWSWIRE) -- Madrigal
Summary Toggle Madrigal Pharmaceuticals Prices Public Offering of Common Stock

June 06, 2018

CONSHOHOCKEN, Pa. , June 06, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases,
Summary Toggle Madrigal Pharmaceuticals Announces Proposed Public Offering of Common Stock

June 05, 2018

CONSHOHOCKEN, Pa. , June 05, 2018 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq:MDGL), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases,

Filing date	Form	Description	Filing Group
May 31, 2002	REGDEX	REGDEX	Other
October 07, 2002	REGDEX	REGDEX	Other
April 21, 2003	REGDEX/A	REGDEX/A	Other